SEC Form EFFECT filed by CM Life Sciences III Inc.
$CMLT
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 1, 2021 4:00 P.M. |
| Form: | S-4 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 1, 2021 4:00 P.M. |
| Form: | S-4 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
EFFECT - EQRx, Inc. (0001843762) (Filer)
424B3 - EQRx, Inc. (0001843762) (Filer)
S-1 - EQRx, Inc. (0001843762) (Filer)
Business combination with CM Life Sciences III results in approximately $1.3 billion in cash proceedsCombined company to trade on Nasdaq Global Market under ticker "EQRX" NEW YORK and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences III (NASDAQ:CMLT, CMLTW, CMLTU))), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, and EQRx, Inc., a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced the completion of their business combination. The business combination was approved by CM Life S
3 - EQRx, Inc. (0001843762) (Issuer)
3 - EQRx, Inc. (0001843762) (Issuer)
SC 13D - EQRx, Inc. (0001843762) (Subject)
SC 13D - EQRx, Inc. (0001843762) (Subject)
SC 13G - CM Life Sciences III Inc. (0001843762) (Subject)